Azitra (AZTR) Cash & Equivalents (2022 - 2026)
Azitra (AZTR) posted Cash & Equivalents of $10.1 million for Q1 2026, up 386.01% on a QoQ basis from $2.1 million in Q4 2025, and up 213.44% year-over-year from $3.2 million in Q1 2025.
Azitra (AZTR) Cash & Equivalents (2022 - 2026) Analysis & Trends
Azitra's Cash & Equivalents history runs 5 years deep, the most recent figure standing at $10.1 million for Q1 2026.
- Quarterly Cash & Equivalents rose 213.44% year-over-year to $10.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.1 million (up 213.44% YoY) and the FY2025 annual result came in at $2.1 million, down 54.59% from the prior year.
- Cash & Equivalents was $10.1 million for Q1 2026 at Azitra, up from $2.1 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $10.1 million in Q1 2026 and bottomed at $803082.0 in Q2 2024.
- A 5-year average of $3.8 million and a median of $3.2 million in 2025 frame the typical range for Cash & Equivalents.
- Annual changes were most pronounced in 2024 — Cash & Equivalents plunged 87.23% — and 2026, when it jumped 213.44%.
- Azitra's Cash & Equivalents stood at $3.5 million in 2022, then slumped by 48.58% to $1.8 million in 2023, then jumped by 153.61% to $4.6 million in 2024, then plunged by 54.59% to $2.1 million in 2025, then surged by 386.01% to $10.1 million in 2026.
- Business Quant data shows AZTR's Cash & Equivalents at $10.1 million in Q1 2026, $2.1 million in Q4 2025, and $1.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Nanobiotix | 1,769.80 Bn | 1,769.74 Bn | - | 60.03 Mn |
| 2 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | 2.83 Mn |
| 3 | BeOne Medicines | 473.64 Bn | 468.85 Bn | 1.35 Bn | 4.79 Bn |
| 4 | Vertex Pharmaceuticals | 123.74 Bn | 116.49 Bn | 2.59 Bn | 5.49 Bn |
| 5 | Regeneron Pharmaceuticals | 71.73 Bn | 62.97 Bn | 3.31 Bn | 2.96 Bn |
| 6 | Belite Bio | 62.10 Bn | 62.10 Bn | - | - |
| 7 | Argenx Se | 54.68 Bn | 49.49 Bn | 1.41 Bn | 3.58 Bn |
| 8 | Alnylam Pharmaceuticals | 38.13 Bn | 35.12 Bn | 959.66 Mn | 1.71 Bn |
| 9 | Revolution Medicines | 36.21 Bn | 36.21 Bn | - | 440.94 Mn |
| 10 | Azitra | 2.03 Mn | 2.03 Mn | - | 10.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.05 Mn |
| Dec 31, 2025 | 2.07 Mn |
| Sep 30, 2025 | 1.40 Mn |
| Jun 30, 2025 | 1.05 Mn |
| Mar 31, 2025 | 3.21 Mn |
| Dec 31, 2024 | 4.55 Mn |
| Sep 30, 2024 | 7.26 Mn |
| Jun 30, 2024 | 803,082.00 |
| Mar 31, 2024 | 3.00 Mn |
| Dec 31, 2023 | 1.80 Mn |
| Sep 30, 2023 | 4.40 Mn |
| Jun 30, 2023 | 6.29 Mn |
| Dec 31, 2022 | 3.49 Mn |